Selexis and KBI Biopharma Enter into Agreements with Immatics for Integrated Approach to Advance Immatics TCR Bispecific Program Towards INDRead More
Increasingly, solutions for complex human diseases are being addressed with increasingly complex protein therapeutic modalities. These include molecules such as bi-specific proteins, DARPins, triabodies and novel scaffolds decorated with peptides, enzymes or growth factors, to name a few. Many, if not most, of these proteins do not exist in nature and producing them presents a range of production and secretion challenges such as ensuring appropriate folding and subunit pairing.
At Selexis, we have spent a lot of time interrogating and characterizing our propriety CHO-K1 cell line (Selexis SURE CHO-M Cell Line); we were one of the first companies to fully sequence the CHO cells's genome and transcriptome. From this data, we have built a comprehensive understanding of the transcriptional and genomic landscape of our cells and where there are mutations or unexpected increases or decreases in host gene transcription levels. This has provided us with detailed insight into potential secretion bottlenecks within our CHO-M cell line, particularly as it applies to difficult-to-express proteins and we have developed technologies to address these bottlenecks, such as our SURE CHO-Mplus Libraries.
Trust Selexis with Your Difficult-to-Express Protein
At Selexis, we believe in the promise of these newer biologics and have committed significant resources to ensure our SUREtechnology Platform can meet the new expression challenges that these non-natural proteins present. We are very proud of our history of empowering scientists and biopharmaceutical companies around the world to realize the full potential of their research and we work hard every day to maintain that legacy.